drugset
drugset / Trial / NCT00812305

Hepatic Impairment Study: Pharmacokinetics in Healthy and Hepatically Impaired Subjects

NCT00812305 ↗

Phase 1 Completed 16 enrolled Pacira Pharmaceuticals, Inc
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Review differences between how a healthy person and how a person with liver problems handles the study drug.

Timeline

Start
2009-01
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject SKY0402 Unknown 300 mg Subcutaneous

Indications

liver disease, severe congenital pain agnosia